LRRK2 antibody (AA 931-962)

Catalog No. ABIN1882109

The Rabbit Polyclonal anti-LRRK2 antibody has been validated for WB and IHC (p). It is suitable to detect LRRK2 in samples from Human. There are 4+ publications available.

Quick Overview for LRRK2 antibody (AA 931-962) (ABIN1882109)

Target: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This LRRK2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB7199

Product Details anti-LRRK2 Antibody

Binding Specificity: AA 931-962

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 931-962 amino acids from human PARK8(LRRK2).

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

References for anti-LRRK2 antibody (ABIN1882109)

Biskup, Moore, Rea, Lorenz-Deperieux, Coombes, Dawson, Dawson, West: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." in: BMC neuroscience, Vol. 8, pp. 102, (2008) (PubMed).

Shen: "Protein kinases linked to the pathogenesis of Parkinson's disease." in: Neuron, Vol. 44, Issue 4, pp. 575-7, (2004) (PubMed).

Wszolek, Pfeiffer, Tsuboi, Uitti, McComb, Stoessl, Strongosky, Zimprich, Müller-Myhsok, Farrer, Gasser, Calne, Dickson: "Autosomal dominant parkinsonism associated with variable synuclein and tau pathology." in: Neurology, Vol. 62, Issue 9, pp. 1619-22, (2004) (PubMed).

Zimprich, Biskup, Leitner, Lichtner, Farrer, Lincoln, Kachergus, Hulihan, Uitti, Calne, Stoessl, Pfeiffer, Patenge, Carbajal, Vieregge, Asmus, Müller-Myhsok, Dickson, Meitinger, Strom, Wszolek, Gasser: "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology." in: Neuron, Vol. 44, Issue 4, pp. 601-7, (2004) (PubMed).

Target Details for LRRK2

Target: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Alternative Name: PARK8 (LRRK2)

Background: Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

Molecular Weight: 286103

NCBI Accession: NP_940980

UniProt: Q5S007

Pathways: Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development